Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cerdelga Becomes First Oral First-Line Therapy For Gaucher Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi’s Genzyme unit obtains U.S. approval for eliglustat as an oral, first-line therapy for adults with Type 1 Gaucher disease. The new product will augment its market-leading Cerezyme, and the company says it will price Cerdelga at par so that patient/physician choice will not be based upon price.

You may also be interested in...



Two Psoriasis Therapies Grab CHMP Backing For European Approval

Novartis’s Cosentyx and Celgene’s Otezla are expected to be approved and launched in Europe in early 2015 for the dermatological indication.

Sanofi’s CEO Search Will Proceed Deliberately, Weinberg Tells Investors

During a late-stage pipeline overview at Genzyme’s headquarters, Sanofi’s chairman and acting CEO laid out the criteria for a new top exec and said reports of a focus on French candidates stem from someone’s imagination.

Differentiation Will Be Key Challenge For Shire's Gaucher Disease Drug Vpriv

The FDA approval of Shire's Vpriv (velaglucerase) means that Genzyme's Cerezyme (imiglucerase) finally has competition in the Gaucher disease space. But market analysts are strongly divided on whether velaglucerase or a pending Pfizer/Protalix drug will be better positioned to make a dent in Cerezyme's market share

Topics

Related Companies

UsernamePublicRestriction

Register

PS077577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel